ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,996.66
1.00%
Dow Jones
43,487.83
0.78%
US Dollar vs MXN
20.74708
1.18%
Brent Oil
78.135
-1.37%
Bitcoin
103,813.56
1.75%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Tango Therapeutics Inc (TNGX)

  7. Tango Therapeutics Inc (TNGX) Noticias

TNGX

Tango Therapeutics (TNGX)

Tango Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:TNGX
FechaHoraFuenteTítuloSímboloCompañía
13/01/202506:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
02/01/202506:07Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TNGXTango Therapeutics Inc
03/12/202406:00Business WireTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TNGXTango Therapeutics Inc
27/11/202406:00Business WireTango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:TNGXTango Therapeutics Inc
20/11/202415:24Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:TNGXTango Therapeutics Inc
18/11/202418:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
07/11/202420:35Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TNGXTango Therapeutics Inc
06/11/202420:40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TNGXTango Therapeutics Inc
06/11/202406:43Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNGXTango Therapeutics Inc
06/11/202406:05Business WireTango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
06/11/202406:00Business WireTango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development ProgramNASDAQ:TNGXTango Therapeutics Inc
22/10/202419:48Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
28/08/202406:00Business WireTango Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:TNGXTango Therapeutics Inc
07/08/202406:00Business WireTango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
05/06/202406:00Business WireTango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:TNGXTango Therapeutics Inc
23/05/202408:18PR Newswire (US)Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical programNASDAQ:TNGXTango Therapeutics Inc
23/05/202406:00Business WireTango Therapeutics Announces Discontinuation of TNG348 ProgramNASDAQ:TNGXTango Therapeutics Inc
08/05/202406:00Business WireTango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
18/03/202406:00Business WireTango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
05/03/202415:47GlobeNewswire Inc.Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:TNGXTango Therapeutics Inc
31/01/202406:00GlobeNewswire Inc.Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceNASDAQ:TNGXTango Therapeutics Inc
04/01/202401:47PR Newswire (US)Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical studyNASDAQ:TNGXTango Therapeutics Inc
03/01/202406:00GlobeNewswire Inc.Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ CancersNASDAQ:TNGXTango Therapeutics Inc
13/11/202306:00GlobeNewswire Inc.Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual MeetingNASDAQ:TNGXTango Therapeutics Inc
08/11/202306:00GlobeNewswire Inc.Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
07/11/202306:00GlobeNewswire Inc.Tango Therapeutics to Present at the Jefferies London Healthcare ConferenceNASDAQ:TNGXTango Therapeutics Inc
18/10/202316:23Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:TNGXTango Therapeutics Inc
18/09/202306:00GlobeNewswire Inc.Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNASDAQ:TNGXTango Therapeutics Inc
11/09/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TNGXTango Therapeutics Inc
06/09/202306:00GlobeNewswire Inc.Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ CancersNASDAQ:TNGXTango Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TNGX

Su Consulta Reciente

NASDAQ
CCWUX
Ci Doubleline Total Retu...
BIT
CIT
UBS LUX Fnd Solut Solact...
BIT
F19242
Vontobel Financial Produ...
BIT
I07198
INTESA SANPAOLO
BIT
SPN
Spindox
BIT
RNO
Renault
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados